Research Article

Apocynin Improves Insulin Resistance through Suppressing Inflammation in High-Fat Diet-Induced Obese Mice

Ran Meng,1,2,3 Da-Long Zhu,1 Yan Bi,1 Dong-Hui Yang,1 and Ya-Ping Wang2,3

1 Department of Endocrinology, Nanjing Drum Tower Hospital, Nanjing University School of Medicine, 321 Zhongshan Road, Nanjing 210008, China
2 Department of Medical Genetics, Nanjing University School of Medicine, 22 Hankou Road, Nanjing 210093, China
3 Jiangsu Key Laboratory of Molecular Medicine, Nanjing University, 22 Hankou Road, Nanjing 210093, China

Correspondence should be addressed to Da-Long Zhu, zhudldr@gmail.com and Ya-Ping Wang, wangyap@nju.edu.cn

Received 27 October 2010; Accepted 17 December 2010

Academic Editor: Chiara De Luca

Copyright © 2010 Ran Meng et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

We investigated the effects of apocynin on high-fat diet- (HFD-) induced insulin resistance in C57BL/6 mice. After 12 weeks of HFD, the mice that exhibited insulin resistance then received 5 weeks of apocynin (2.4 g/L, in water). Following apocynin treatment, fasting glucose, insulin, and glucose tolerance test showed significant improvement in insulin sensitivity in HFD-fed mice. We demonstrated that serum levels of tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and leptin were remarkably reduced with apocynin treatment. We also found that mRNA expression of TNF-α, IL-6, and monocyte chemoattractant protein-1 (MCP-1) in the liver and mRNA expression of TNF-α, IL-6, MCP-1, and leptin in adipose tissue were suppressed by apocynin. Furthermore, the activity of transcription factor NF-κB in the liver was significantly suppressed with apocynin treatment. These results suggest that apocynin may reduce inflammatory factors in the blood, liver, and adipose tissue, resulting in amelioration of insulin resistance in HFD-fed mice.

1. Introduction

Insulin resistance is one of the critical mechanisms of the type 2 diabetes [1]. Increasing evidence suggests that inflammation plays an important role in the development of insulin resistance [2]. The inflammatory status of the liver and adipose tissue, the main insulin-resistance-related organs, is critical for insulin sensitivity of the whole body [3, 4].

During development of inflammation in the liver, hepatocytes are exposed to the increasing cytokines such as tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and monocyte chemoattractant protein-1 (MCP-1) [5]. These cytokines were regulated by nuclear factor kappa-B (NF-κB) [6, 7]. A number of studies demonstrated that hepatic NF-κB activation was linked to the development of the whole body inflammation, resulting in insulin resistance [8, 9]. Additionally, adipose tissue is an active endocrine organ that secretes numerous inflammation-related adipokines, cytokines, and chemokines. The expression of TNF-α, IL-6, MCP-1, and leptin is upregulated in the adipose tissue of obese mice which is closely associated with insulin resistance [10–12].

Interestingly, some studies reported that oxidative stress could induce inflammation during development of insulin resistance [13, 14]. Oxidative stress which is induced by excess reactive oxygen species (ROS) could activate NF-κB [15]. Antioxidants have been reported to potently suppress the activation of NF-κB in the liver [16–18]. Furthermore, increased oxidative stress in adipocytes causes dysregulation of cytokines and adipokines, including adiponectin, MCP-1, IL-6, and plasminogen activator inhibitor-1 (PAI-1) [19, 20]. Accordingly, antioxidants have been also reported to decrease inflammation in adipose tissue and ultimately ameliorate insulin resistance [21, 22].

Apocynin (4-hydroxy-3-methoxy-acetophenone) is a constituent of the Himalayan herb Picrorhiza kurrooa Royle (Scrophulariaceae) which is regarded as an inhibitor of nicotinamide adenine dinucleotide phosphate (NADPH)-oxidase and is widely used as an antioxidant in research. In addition, apocynin also exhibits anti-inflammatory effects in previous studies [23, 24]. It was demonstrated that
apocynin suppressed NF-κB in spontaneously hypertensive rats [25], downregulated TNF-α protein expression in coronary arteries [26], decreased vascular cell adhesion molecule-1 (VCAM-1) induced by TNF-α in vein endothelial cells [27], reduced polymorphonuclear granulocyte chemotaxis [28], inhibited peroxynitrite in airway lumen in mice [29], attenuated inflammation-mediated cartilage destruction activity in human articular cartilage [30], and reduced cyclooxygenase (COX)-2 expression in human monocytes [31]. Since the critical role of inflammation in genesis of insulin resistance, it is reasonable to speculate that apocynin could improve insulin resistance through suppressing inflammation. However, no studies were conducted to examine the effects of apocynin on inflammation and its subsequent effects on insulin resistance.

In this study, C57BL/6 mice were fed with high-fat diet (HFD) to establish insulin resistance for investigating the effects of apocynin on the expression of inflammatory factors in blood, liver, and adipose tissue, and then evaluating the improvement of insulin sensitivity with apocynin treatment.

2. Methods

2.1. Animals and Experimental Procedures. Four-week-old male C57BL/6 mice used in this study were purchased from animal center, Yangzhou University (Yangzhou, Jiangsu, China). The mice were fed either with high-fat diet (60% kcal fat, 20% kcal carbohydrates, 20% kcal protein, Guangzhou animal experiment center, Guangzhou, China), or with normal chow diet (10% kcal fat, 70% kcal carbohydrates, 20% kcal protein) after one week’s acclimation period. Mice were fasted for 12 hours. After given ketamine-xylazine (130/8.8 mg/kg), five weeks with HFD. Mice were sacrificed after fasting for 6 hours prior to IPGTTs. Glucose was injected intraperitoneally with the concentration of 1 g/kg body weight. Blood glucose measurement were obtained from the tail at 0, 30, 60, and 120 min. Blood glucose levels were determined at indicated intervals with One Touch Profile Glucose Meter (Johnson & Johnson, New Brunswick, NJ, USA).

2.4. Quantitative PCR Analysis. Total RNA was extracted from the liver and epididymal adipose tissue of mice by Trizol (Takara Bio, Shiga, Japan). Synthesis of cDNA was performed by M-MLV reverse transcriptase (Toyobo, Osaka, Japan). Quantitative real-time PCR was performed with SYBR Premix Ex Taq (Takara Bio, Shiga, Japan), using the StepOne Real-Time PCR system according to the manufacturer’s instructions (Applied Biosystems, Foster City, CA, USA). The primer pairs used in the present study are listed in Table 1. Final results were normalized against β-actin gene expression.

2.2. Plasma Parameters. Mice were fasted for 12 hours, and blood samples were collected from the orbital sinus under anesthesia. After centrifugation at 15,000× g for 1 min, the supernatants of the blood samples were separated and subjected to measurements of leptin, TNF-α, and IL-6 levels with the ELISA kits (RayBiotech, Norcross, GA, USA). Plasma insulin was determined with Mouse Insulin ELISA Assay kit (Linco, Charles, MO, USA).

2.3. Intraperitoneal Glucose Tolerance Tests (IPGTTs). Mice were fasted for 6 hours prior to IPGTTs. Glucose was injected intraperitoneally with the concentration of 1 g/kg body weight. Blood glucose measurement were obtained from the tail at 0, 30, 60, and 120 min. Blood glucose levels were determined at indicated intervals with One Touch Profile Glucose Meter (Johnson & Johnson, New Brunswick, NJ, USA).

2.5. NF-κB Activity Assay. Nuclear protein extracts were prepared from liver tissue with the nuclear extract kit (Active Motif, Carlsbad, CA) according to the manufacturer’s instructions. Protein concentrations were then quantified with a Bradford assay, and equal amounts of protein were used in a colorimetric NF-κB assay specific for the activated form of p65 subunit of NF-κB (Trans AM NF-κB p65 kit; Active Motif, Carlsbad, CA).

2.6. Statistical Analysis. Data are expressed as the means ± SEM. P values were determined by one-way ANOVA followed by LSD and differences were considered significant if P < .05.

3. Results

3.1. Effect of Apocynin on Growth Parameters. The effect of apocynin on body weight in HFD-fed mice was shown in Figure 1(a). The body weight of HFD-Apo group and HFD-Con group were similar (P > .05) and significantly higher than that in the ND-Con group until 3 weeks after the treatment of apocynin (P < .05). From the fourth week to the end of the experiment, the body weight of HFD-Apo group was clearly lower than that of HFD-Con group (P < .05). The mean dietary intake during the experiment was significantly lower in the HFD-Con and HFD-Apo groups than that in the ND-Con group (P < .05, Figure 1(b)), while energy intake has no significant difference among groups (P > .05, Figure 1(c)).
Table 1: Primer pairs used in present study.

| Gene       | Forward primer       | Reverse primer       |
|------------|----------------------|----------------------|
| TNF-α      | CAGGAGGAGACAGAATCTCCA| CCTGGTTGGCTTGTTCTTT  |
| IL-6       | TCCAGTTGCTGCTGCTT    | GTGGTAATAGCCCTGGTATT |
| MCP-1      | CAATCAATGCCGCTGCAC   | GATTCTGCTGCTGCTGCTT |
| Leptin     | GATGACACCAAAACCTCATC | GCCACCACCTCGTTAGGCTT |
| Adiponectin| GTCAGTGGATCTGACACAGCA| ATGGCCTGCCACCTCGTTAG |
| Actin      | CATCCGTAAAGACCTCCTG  | ATGGGACCACCCAGATCCAA |

Figure 1: Effect of apocynin on body weight, food intake, and energy intake. C57BL/6 mice were fed with HFD for 12 weeks to induce insulin resistance. After 12 weeks of feeding, the HFD-fed mice were divided into two groups. The HFD-fed mice in one group were treated with apocynin (2.4 g/L) in drink water (HFD-Apo, n = 6) for another 5 weeks HFD feeding; the HFD-fed mice in the other group were employed as HFD controls (HFD-Con, n = 6). Normal control mice were fed a normal diet and untreated with apocynin (ND-Con, n = 6).

(a) Body weight of three groups. The body weight of the HFD-Apo group was lower than that of the HFD-Con group since the fourth week after apocynin treatment.

(b) Food intake. The food intake of the HFD-Apo group and HFD-Con group were lower than that in the ND-Con group.

(c) Energy intake. There are no differences among groups. *P < .05 versus ND-Con group, *P < .05 versus HFD-Con group.

3.3. Effects of Apocynin on Systemic Inflammation. Serum inflammatory cytokines levels are shown in Figures 3(a)–3(c). The levels of TNF-α, IL-6, and leptin in HFD-Con group were remarkably higher than ND-Con group (P < .05, resp.). Apocynin treatment significantly decreased the levels.
4 Mediators of Inflammation

Figure 2: Effect of apocynin on obesity-induced glucose intolerance. (a) IPGTTs was performed by injection intraperitoneally of 1 g/kg glucose after 6-hour fasting, and blood samples were drawn from tail veins after 0, 30, 60, and 120 min. (b) Area under the curve was measured as a parameter of insulin resistance. Significant difference was detected between HFD-Apo group and HFD-Con group. (c) Fasting glucose levels. There is a significant difference between HFD-Apo group and HFD-Con group. (d) Fasting insulin levels. The fasting insulin level of the HFD-Apo group is lower than that of HFD-Con group. # P < .05 versus ND-Con group, * P < .05 versus HFD-Con group.

3.4. Effects of Apocynin on Inflammation-Related Gene Expression in Adipose Tissue. In adipose tissue, the HFD-Con group exhibited significantly higher gene expression of TNF-α, IL-6, MCP-1, and leptin and lower expression of adiponectin than ND-Con group (P < .05, resp.). Apocynin treatment obviously decreased TNF-α, IL-6, MCP-1, and leptin expression (P < .05, resp.) (Figures 4(a)–4(d)). However, there was no change in expression of adiponectin after treatment with apocynin (P > .05) (Figure 4(e)).

3.5. Effects of Apocynin on Inflammation-Related Gene Expression and NF-κB Activity in the Liver. In the liver, gene expression TNF-α, IL-6, and MCP-1 were significantly lower in the HFD-Apo than the HFD-Con group (P < .05, resp.) (Figures 5(a)–5(c)). We further tested NF-κB activity in liver nuclear extract samples from the mice of three experiment groups. We found that significantly less NF-κB activity was derived from apocynin-treated mice than those derived from untreated HFD-fed mice (P < .05) (Figure 5(d)).

4. Discussion

Our present study indicates that apocynin administration in HFD-fed C57BL/6 mice can improve insulin sensitivity, reduce the diverse plasma inflammatory cytokines, suppress gene expression of inflammation-related molecules in both liver and adipose tissue, and decrease the activity of transcription factor NF-κB in liver tissue. These results suggest that apocynin could ameliorate insulin resistance through the suppression of inflammation in HFD-fed C57BL/6 mice.
To reflect modern dietary conditions, we employed C57BL/6 mice fed with HFD (60% kcal from fat) for 12 weeks which is a simple insulin resistance model. HFD-fed mice exhibited higher body weight than normal diet mice. Although food and energy intakes were not significantly different, the body weight of the HFD-Con group was increased, whereas that of the HFD-Apo group was decreased and close to ND-Con group. The HFD-fed mice exhibited significantly higher fasting glucose, fasting insulin levels, and AUC of IPGTT than normal control mice. Apocynin treatment dramatically decreased these indexes of insulin resistance.

Apocynin is an antioxidant which can be used as an inhibitor of NADPH oxidase. Recently, there have been a few studies that implicated that apocynin may improve insulin resistance which are consistent with the results of the present study. Winiarska and colleagues found that apocynin could inhibit renal gluconeogenesis action by suppressing oxidative stress, resulting in hypoglycaemic response in diabetic rabbits [32]. Another study indicated that apocynin administration decreased lipid peroxidation and hydrogen peroxide in adipose tissue which led to the improvement of plasma glucose and insulin resistance in KKAy mice, a transgenic animal model of type 2 diabetes [33]. Also, the antioxidative effect of apocynin was protective in diabetic nephropathy [34, 35], in diabetic endothelial dysfunction [36, 37], and in diabetic mitochondrial dysfunction in skeletal muscle [38]. However, none of the previous studies focused on the anti-inflammatory effect of apocynin on insulin resistance.

Inflammation has been defined as an important contributor to insulin resistance in last century. Overproduction of inflammatory factors can cause insulin resistance. In contrast, suppressing inflammatory factors may ameliorate insulin resistance [39, 40]. The molecular pathways that link inflammation and insulin resistance include a variety of cytokines and adipocytokines such as TNF-α, IL-6, MCP-1, leptin, and adiponectin [2]. High circulating levels of TNF-α, IL-6, and leptin are recognized as markers of insulin resistance [10, 41, 42].

The liver and adipose tissue are two major insulin action organs. The inflammatory status of the liver and adipose tissue could directly impact the systemic inflammatory status that accompanies insulin resistance. Inflammation-related
transcription factor NF-κB in the liver is regarded as an important factor for inducing insulin resistance. Increased hepatic NF-κB activity could cause profound hepatic insulin resistance and moderate systemic insulin resistance [8]. Furthermore, as a transcription factor, NF-κB regulates expression of many kinds of cytokines in the liver. Once NF-κB is activated, the gene expression of TNF-α, IL-6, and MCP-1 is inordinately increased [6, 7]. The endocrine function of adipose tissue and the association of obesity result in chronic low-grade inflammation and reinforce the concept of the central role of adipose tissue in mediating obesity-linked insulin resistance [43]. It has been discovered...
that the adipose tissue in fact contributes 15–35% of the body's basal circulating IL-6 and a large rate of whole body TNF-α [44]. Adipose tissue macrophages (ATMs) are proved to be predominantly responsible for the elevated production of TNF-α [45] and IL-6 during obesity [46]. MCP-1 could contribute macrophage infiltration into adipose tissue and affect the number of ATMs in adipose tissue, which in turn impacts the expression of TNF-α and IL-6. Moreover, leptin is almost exclusively expressed in adipose tissue. So gene expression of leptin in adipose tissue directly affects leptin level in the blood.

Apocynin is a traditional antioxidant. However, Hart and his colleagues found that apocynin could reduce inflammation as well as superoxide anion [47]. Afterwards, a number of studies have demonstrated that apocynin could modulate the production of inflammatory factors production both in vitro [27–31] and in vivo [25, 33, 48]. In the present study, we investigated the effect of apocynin on the inflammatory status through HFD-induced insulin resistance in C57BL/6 mice. Our results show that the gene expression of TNF-α, IL-6, and MCP-1 in the liver and the gene expression of TNF-α, IL-6, MCP-1, and leptin in adipose tissue were upregulated after HFD feeding in mice. Apocynin administration suppressed the expression of these inflammatory agents, resulting in the reduction of circulating TNF-α, IL-6, and leptin levels that normally accompany insulin resistance.

Furthermore, we found that apocynin could reduce the activity of hepatic NF-κB which contributes to the improvement of insulin resistance both in the liver and whole body. How can the antioxidant apocynin decrease the NF-κB activity? There is compelling evidence that in many cell types, ROS such as hydrogen peroxide and superoxide anion have a major effect on the release and nuclear translocation of the NF-κB complex and on the induction of NF-κB target genes [49, 50]. NADPH oxidase, a major source of ROS, triggers the production of superoxide anion [51, 52]. Hence, it is reasonable that apocynin, an inhibitor of NADPH oxidase, suppresses NF-κB activity. Our results are in agreement with a study conducted by Pechanova and his colleagues who used apocynin in spontaneously hypertensive rats. After six weeks of treatment, apocynin significantly decreased the activity of NF-κB in the left ventricle [25]. Although in the present study, we have proved that apocynin could ameliorate inflammatory status and suppress the activity of NF-κB in the liver, changes in other inflammatory signaling

### Figure 5: Effects of apocynin on inflammation-related genes expression and the activity of NF-κB in the liver. Apocynin treatment decreased the gene expression of (a) TNF-α, (b) IL-6, (c) MCP-1 in HFD-Apo group compared to HFD-Con group. (d) Hepatic NF-κB activity was tested by the special kit (Trans-AM NF-κB kit). The hepatic NF-κB activity is lower in the HFD-Apo group than that in the HFD-Con group.
pathways and insulin signaling remain unknown. Further investigations will be conducted in our lab.

In conclusion, apocynin has the potential to improve insulin sensitivity through ameliorating inflammatory status in the blood, liver, and adipose tissue of the C57BL/6 mice in which insulin resistance was induced by HFD. Hence, apocynin is a promising agent for treating insulin resistance.

Acknowledgments

This study was supported by National Natural Science Foundation of China (30671004) and Natural Science Foundation of Jiangsu Province of China (BS2006006).

References

[1] P. T. James, N. Rigby, and R. Leach, “The obesity epidemic, metabolic syndrome and future prevention strategies,” European Journal of Cardiovascular Prevention and Rehabilitation, vol. 11, no. 1, pp. 3–8, 2004.
[2] S. E. Shoelson, J. Lee, and A. B. Goldfine, “Inflammation and insulin resistance,” Journal of Clinical Investigation, vol. 116, no. 7, pp. 1793–1801, 2006.
[3] H. Tilg and A. R. Moschen, “Insulin resistance, inflammation, and non-alcoholic fatty liver disease,” Trends in Endocrinology and Metabolism, vol. 19, no. 10, pp. 371–379, 2008.
[4] H. Xu, G. T. Barnes, Q. Yang et al., “Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance,” Journal of Clinical Investigation, vol. 112, no. 12, pp. 1821–1830, 2003.
[5] J. H. Kang, G. Tsuyoshi, I. S. Han, T. Kawada, Y. M. Kim, and R. Yu, “Dietary capsaicin reduces obesity-induced insulin resistance and hepatic steatosis in obese mice fed a high-fat diet,” Obesity, vol. 18, no. 4, pp. 780–787, 2010.
[6] H. Tilg and A. R. Moschen, “Inflammatory mechanisms in the regulation of insulin resistance,” Molecular Medicine, vol. 14, no. 3-4, pp. 222–231, 2008.
[7] I. A. Leclercq, G. C. Farrell, C. Sempoux, A. D. Peña, and Y. Horsmans, “Curcumin inhibits NF-κB activation and reduces the severity of experimental steatohepatitis in mice,” Journal of Hepatology, vol. 41, no. 6, pp. 926–934, 2004.
[8] D. Cai, M. Yuan, D. F. Frantz et al., “Local and systemic insulin resistance resulting from hepatic activation of IKK-β and NF-κB,” Nature Medicine, vol. 11, no. 2, pp. 183–190, 2005.
[9] M. C. Arkan, A. L. Heyer, F. R. Greten et al., “IKK-β links inflammation to obesity-induced insulin resistance,” Nature Medicine, vol. 11, no. 2, pp. 191–198, 2005.
[10] G. S. Hotamisligil, N. S. Shargill, and B. M. Spiegelman, “Adipose expression of tumor necrosis factor-α: direct role in obesity-linked insulin resistance,” Science, vol. 259, no. 5091, pp. 87–91, 1993.
[11] N. Kamei, K. Tobe, R. Suzuki et al., “Overexpression of monocyte chemoattractant protein-1 in adipose tissue causes macrophage recruitment and insulin resistance,” Journal of Biological Chemistry, vol. 281, no. 36, pp. 26602–26614, 2006.
[12] J. P. Bastard, M. Maachi, J. T. van Nhieu et al., “Adipose tissue IL-6 content correlates with resistance to insulin activation of glucose uptake both in vivo and in vitro,” Journal of Clinical Endocrinology and Metabolism, vol. 87, no. 5, pp. 2084–2089, 2002.
[13] S. N. Murthy, C. V. Desouza, N. W. Bost et al., “Effects of salsalate therapy on recovery from vascular injury in female Zucker fatty rats,” Diabetes, vol. 59, no. 12, pp. 3240–3246, 2010.
[14] E. Hopps, D. Noto, G. Caimi, and M. R. Averna, “A novel component of the metabolic syndrome: the oxidative stress,” Nutrition, Metabolism and Cardiovascular Diseases, vol. 20, no. 1, pp. 72–77, 2010.
[15] E. Ho and T. M. Bray, “Antioxidants, NF-κB activation, and diabetogenesis,” Proceedings of the Society for Experimental Biology and Medicine, vol. 222, no. 3, pp. 205–213, 1999.
[16] G. M. Campo, A. Avenoso, S. Campo et al., “The antioxidant activity of chondroitin-4-sulfate, in carbon tetrachloride-induced acute hepatitis in mice, involves NF-κB and caspase activation,” British Journal of Pharmacology, vol. 155, no. 6, pp. 945–956, 2008.
[17] H. Shapiro, M. Ashkenazi, N. Weizman, M. Shahmurov, H. Aed, and R. Bruck, “Curcumin ameliorates acute thioacetamide-induced hepatotoxicity,” Journal of Gastroenterology and Hepatology, vol. 21, no. 2, pp. 358–366, 2006.
[18] R. Bruck, H. Aed, Y. Avni et al., “Melatonin inhibits nuclear factor kappa B activation and oxidative stress and protects against thioacetamide induced liver damage in rats,” Journal of Hepatology, vol. 40, no. 1, pp. 86–93, 2004.
[19] M. Kamigaki, S. Sakae, I. Tsujiino et al., “Oxidative stress provokes atherogenic changes in adipokine gene expression in 3T3-L1 adipocytes,” Biochemical and Biophysical Research Communications, vol. 339, no. 2, pp. 624–632, 2006.
[20] Y. Uchida, K. I. Ohba, T. Yoshioka, K. Irie, Y. Muraki, and Y. Maru, “Cellular carbonyl stress enhances the expression of plasminogen activator inhibitor-1 in rat white adipocytes via reactive oxygen species-dependent pathway,” Journal of Biological Chemistry, vol. 279, no. 6, pp. 4075–4083, 2004.
[21] T. Sakurai, K. Kitade, H. Nishio et al., “Oligomerized grape seed polyphenols attenuate inflammatory changes due to antioxidative properties in coculture of adipocytes and macrophages,” Journal of Nutritional Biochemistry, vol. 21, no. 1, pp. 47–54, 2010.
[22] T. Sakurai, H. Nishio, H. Fujii et al., “Antioxidative effects of a new lychee fruit-derived polyphenol mixture, oligonol, converted into a low-molecular form in adipocytes,” Bioscience, Biotechnology and Biochemistry, vol. 72, no. 2, pp. 463–476, 2008.
[23] S. Hougee, A. Hartog, A. Sanders et al., “Oral administration of the NADPH-oxidase inhibitor apocynin partially restores diminished cartilage proteoglycan synthesis and reduces inflammation in mice,” European Journal of Pharmacology, vol. 531, no. 1–3, pp. 264–269, 2006.
[24] D. Viáčková, M. Pekarová, T. Čhák et al., “Redox-sensitive regulation of macrophage-inducible nitric oxide synthase expression in vitro does not correlate with the failure of apocynin to prevent lung inflammation induced by endotoxin,” Immunobiology, In press.
[25] O. Pechánová, L. Jendeková, and S. Vranková, “Effect of chronic apocynin treatment on nitric oxide and reactive oxygen species production in borderline and spontaneous hypertension,” Pharmacological Reports, vol. 61, no. 1, pp. 116–122, 2009.
[26] A. Picchi, X. Gao, S. Belmadani et al., “Tumor necrosis factor-α induces endothelial dysfunction in the prediabetic metabolic syndrome,” Circulation Research, vol. 99, no. 1, pp. 69–77, 2006.
[27] C. Weber, W. Erl, A. Pietzsch, M. Strobel, H. W. L. Ziegler-Heitbrock, and P. C. Weber, “Antioxidants inhibit monocyte adhesion by suppressing nuclear factor-κB mobilization and induction of vascular cell adhesion molecule-1 in endothelial
Mediators of Inflammation

cells stimulated to generate radicals,” *Arteriosclerosis and Thrombosis*, vol. 14, no. 10, pp. 1665–1673, 1994.

[28] A. A. Müller, S. A. Reiter, K. G. Heider, and H. Wagner, “Plant-derived acetophenones with antiasthmatic and anti-inflammatory properties: inhibitory effects on chemotaxis, right angle light scatter and actin polymerization of polymorphonuclear granulocytes,” *Planta Medica*, vol. 65, no. 7, pp. 590–594, 1999.

[29] R. B. R. Muijser, I. van Ark, G. Folkerts et al., “Apocynin and 1400 W prevents airway hyperresponsiveness during allergic reactions in mice,” *British Journal of Pharmacology*, vol. 134, no. 2, pp. 434–440, 2001.

[30] F. P. J. G. Lafeber, C. J. Beukelman, E. van den Worm et al., “Apocynin, a plant-derived, cartilage-saving drug, might be useful in the treatment of rheumatoid arthritis,” *Rheumatology*, vol. 38, no. 11, pp. 1088–1093, 1999.

[31] S. S. Barbieri, V. Cavalca, S. Eligini et al., “Apocynin prevents cyclooxygenase 2 expression in human monocytes through NADPH oxidase and glutathione redox-dependent mechanisms,” *Free Radical Biology and Medicine*, vol. 37, no. 2, pp. 156–165, 2004.

[32] K. Winiarska, M. Grabowski, and M. K. Rogacki, “Inhibition of renal gluconeogenesis contributes to hypoglycaemic action of NADPH oxidase inhibitor, apocynin,” *Chemico-Biological Interactions*. In press.

[33] S. Furukawa, T. Fujita, M. Shimabukuro et al., “Increased oxidative stress in obesity and its impact on metabolic syndrome,” *Journal of Clinical Investigation*, vol. 114, no. 12, pp. 1752–1761, 2004.

[34] V. Thallas-Bonke, S. R. Thorpe, M. T. Coughlan et al., “Inhibition of NADPH oxidase prevents advanced glycation end product-mediated damage in diabetic nephropathy through a protein kinase C-α-dependent pathway,” *Diabetes*, vol. 57, no. 2, pp. 460–469, 2008.

[35] J. Edlund, A. Fasching, P. Liss, P. Hansell, and F. Palm, “The roles of NADPH-oxidase and nNOS for the increased oxidative stress and the oxygen consumption in the diabetic kidney,” *Diabetes/Metabolism Research and Reviews*, vol. 26, no. 5, pp. 349–356, 2010.

[36] M. Olukman, C. E. Orhan, F. G. Celenk, and S. Ulker, “Apocynin restores endothelial dysfunction in streptozotocin diabetic rats through regulation of nitric oxide synthase and NADPH oxidase expressions,” *Journal of Diabetes and Its Complications*, vol. 24, no. 6, pp. 415–423, 2010.

[37] T. Hayashi, P. A. R. Juliet, H. Kano-Hayashi et al., “NADPH oxidase inhibitor, apocynin, restores the impaired endothelial-dependent and -independent responses and scavenges superoxide anion in rats with type 2 diabetes complicated by NO dysfunction,” *Diabetes, Obesity and Metabolism*, vol. 7, no. 4, pp. 334–343, 2005.

[38] T. Yokota, S. Kinugawa, K. Hirabayashi et al., “Oxidative stress in skeletal muscle impairs mitochondrial respiration and limits exercise capacity in type 2 diabetic mice,” *American Journal of Physiology—Heart and Circulatory Physiology*, vol. 297, no. 3, pp. H1069–H1077, 2009.

[39] S. Schenk, M. Saberi, and J. M. Olefsky, “Insulin sensitivity: modulation by nutrients and inflammation,” *Journal of Clinical Investigation*, vol. 118, no. 9, pp. 2992–3002, 2008.

[40] K. E. Wollen and G. S. Hotamisligil, “Inflammation, stress, and diabetes,” *Journal of Clinical Investigation*, vol. 115, no. 5, pp. 1111–1119, 2005.

[41] H. P. Kopp, C. W. Kopp, A. Festa et al., “Impact of weight loss on inflammatory proteins and their association with the insulin resistance syndrome in morbidly obese patients,” *Arteriosclerosis, Thrombosis, and Vascular Biology*, vol. 23, no. 6, pp. 1042–1047, 2003.

[42] R. V. Considine, M. K. Sinha, M. L. Heiman et al., “Serum immunoreactive-leptin concentrations in normal-weight and obese humans,” *New England Journal of Medicine*, vol. 334, no. 5, pp. 292–295, 1996.

[43] H. Tilg and A. R. Moschen, “Adipocytokines: mediators linking adipose tissue, inflammation and immunity,” *Nature Reviews Immunology*, vol. 6, no. 10, pp. 772–783, 2006.

[44] B. Antuna-Puente, B. Feve, S. Fellahi, and J. P. Bastard, “Adipokines: the missing link between insulin resistance and obesity,” *Diabetes and Metabolism*, vol. 34, no. 1, pp. 2–11, 2008.

[45] N. Luo, J. Liu, B. H. Chung et al., “Macrophage adiponectin expression improves insulin sensitivity and protects against inflammation and atherosclerosis,” *Diabetes*, vol. 59, no. 4, pp. 791–799, 2010.

[46] S. Akira, T. Taga, and T. Kishimoto, “Interleukin-6 in biology and medicine,” *Advances in Immunology*, vol. 54, pp. 1–78, 1993.

[47] B. A. Hart and J. M. Simons, “Metabolic activation of phenols by stimulated neutrophils: a concept for a selective type of anti-inflammatory drug,” *Biotechnology Therapeutics*, vol. 3, no. 3–4, pp. 119–135, 1992.

[48] A. Pandey, K. Kour, S. Bani et al., “Amelioration of adjuvant induced arthritis by apocynin,” *Phytotherapy Research*, vol. 23, no. 10, pp. 1462–1468, 2009.

[49] A. K. Roy, “Transcription factors and aging,” *Molecular Medicine*, vol. 3, no. 8, pp. 496–504, 1997.

[50] R. Schreck, P. Rieber, and P. A. Baueuerle, “Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF-κB transcription factor and HIV-1,” *EMBO Journal*, vol. 10, no. 8, pp. 2247–2258, 1991.

[51] R. A. Clark and A. J. Valente, “Nuclear factor kappa B activation by NADPH oxidases,” *Mechanisms of Ageing and Development*, vol. 125, no. 10–11, pp. 799–810, 2004.

[52] S. S. Brar, T. P. Kennedy, A. B. Sturrock et al., “NADPH oxidase promotes NF-κB activation and proliferation in human airway smooth muscle,” *American Journal of Physiology—Lung Cellular and Molecular Physiology*, vol. 282, no. 4, pp. L782–L795, 2002.